Apart from AML, in CML, combined blockade of BCL-2 by Venetoclax and BCR-ABL tyrosine kinase using a TKI effectively eradicates CML LSCs in vitro and in vivo [240]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.